Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Found endogenously in human plasma (~200 ng/mL at age 20), saliva, and urine, GHK-Cu forms a high-affinity complex with copper(II) ions through its histidine imidazole nitrogen and peptide backbone coordination
Nervous system disorders Uncommon: Headache Not known: Convulsions*, Dizziness Heart disease Not known: Palpitations Vascular pathologies Uncommon: Hypertension, Hypotension Respiratory, thoracic and mediastinal pathologies Not known: Dyspnea Gastrointestinal disorders Common: Vomiting, Nausea, Diarrhea, Abdominal pain Uncommon: Dysgeusia, Dyspepsia, Dry mouth Skin and subcutaneous tissue disorders Uncommon: Abnormal skin odor ** Not known: Itching, Skin rash Musculoskeletal and connective tissue disorders Uncommon: Muscle spasms Not known: Myasthenia***, Muscle tension Systemic disorders and conditions related to the administration site Uncommon: Chest pain, Feeling abnormal, Pyrexia, Injection site reaction**** Diagnostic tests Uncommon: Increased blood pressure Very rare: Increased INR*****
Major pharmacy chains are reporting delays
GHK-Cu (injectable form), KPV, Thymosin Alpha -1, and thymosin beta-4 fragments were classified under the FDA 503A compounding Category 2 framework (restricted from routine compounding due to safety concerns or insufficient clinical evidence) following regulatory actions in 2023-2024
US$ 23.07
US$ 28.57
US$ 21.94
US$ 24.76
